DANUGLIPRON
Danuglipron is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target glucagon-like peptide 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 5 | 2 | — | — | — | 7 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | 2 | — | — | — | 6 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 4 | 2 | — | — | — | 6 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Overweight | D050177 | — | E66.3 | 5 | — | — | — | — | 5 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DANUGLIPRON |
| INN | danuglipron |
| Description | Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.
|
| Classification | Small molecule |
| Drug class | glucagon-like peptide receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 2230198-02-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4518483 |
| ChEBI ID | — |
| PubChem CID | 134611040 |
| DrugBank | — |
| UNII ID | DN9IUI24GP (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 143 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use